Shortage of Quinapril/Hydrochlorothiazide Tablets
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Quinapril/Hydrochlorothiazide tablets, used in the cardiovascular category, are currently in shortage due to discontinuation of manufacturing, affecting all listed presentations.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 16, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Quinapril/Hydrochlorothiazide.
Shortage of Quinapril/Hydrochlorothiazide Tablets
What's in Shortage
The generic drug name is Quinapril/Hydrochlorothiazide Tablet. The brand name is QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE. It is available in tablet dosage form and falls under the therapeutic category of Cardiovascular. The shortage status is current, with the initial posting date of 01/19/2023 and last updated on 04/15/2026.
Which Manufacturers Are Affected
The affected manufacturer is Aurobindo Pharma USA. Their availability status is Unavailable for all presentations. Specifically:
- Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)
- Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)
- Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90) Contact information for Aurobindo Pharma USA is 866-850-2876.
Why There's a Shortage
The shortage is due to the discontinuation of the manufacture of the drug.
What Patients Should Do
Patients who rely on this medication should speak with their pharmacist or healthcare provider to discuss options. They may also contact the manufacturer directly using the provided information. Remember, patients should always consult their healthcare provider for personalized advice and not make changes to their treatment without professional guidance.
Source
This information is sourced from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,474 characters here).
Similar severity timing
Same severity (high) notices issued closest in time to April 16, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.